32 results
Keyword Blinatumomab Remove keyword
-
List item
National expert: Monika Brüggemann, European Medicines Agency (updated)
- Declaration of interests - 82.67 KB | PDF
- Curriculum Vitae - 31.08 KB | PDF
C, Zugmaier G, Bassan R. Blinatumomab versus historic standard-of-care … MS. Molecular response with blinatumomab in relapsed/refractory B-cell … 08/2020-(current) Amgen Inc Blinatumomab Relapsed/refractory and MRD … -
List item
National expert: Carmelo Rizzari, European Medicines Agency (updated)
- Declaration of interests - 81.84 KB | PDF
- Curriculum Vitae - 55.46 KB | PDF
Novartis), Nilotinib (Novartis), Blinatumomab (Amgen), Bortezomib (Academic … LEKEMIA 06/2019-11/2020 AMGEN BLINATUMOMAB acute lymphoblastic leukemia … -
List item
National expert: Ulrich Jaeger, European Medicines Agency (updated)
- Declaration of interests - 87.11 KB | PDF
- Curriculum Vitae - 21.07 KB | PDF
Lymphoma 01/2015-12/2015 Amgen Blinatumomab ALL 01/2014-06/2014 AOP … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018
CHMP, Last updated: 16/11/2018blinatumomab) in patients with residual … -
List item
National expert: Vassilios PAPADAKIS, National Organization for Medicines (updated)
- Declaration of interests - 81.5 KB | PDF
- Curriculum Vitae - 35.34 KB | PDF
-
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
CHMP, Last updated: 21/09/2018blinatumomab … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
CHMP, Last updated: 27/07/2018of medicine Blincyto INN blinatumomab Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015
CHMP, Last updated: 25/09/2015blinatumomab) for the treatment of Philadelphia … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020
CHMP, Last updated: 16/10/2020Blincyto INN blinatumomab Marketing-authorisation holder … -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 15/01/2021 -
List item
List of medicines under additional monitoring
Last updated: 16/12/2020 -
List item
COMP: Agendas, minutes and meeting reports
Last updated: 08/10/2020 -
List item
Recommendations on medication errors
Last updated: 24/06/2020Blincyto, INN-blinatumomab 30 Churchill Place … cancer medicine Blincyto (blinatumomab) is used in a safe and effective …
-
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 07/01/2021 -
List item
Medicines under evaluation
Last updated: 16/03/2020 -
List item
PDCO: Agendas, minutes and meeting reports
Last updated: 11/11/2020 -
List item
Newsletters
Last updated: 10/12/2020 -
List item
Press release: Conditional marketing authorisations give patients access to important new medicines earlier
Last updated: 23/01/2017 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 January 2021
PRAC, Last updated: 15/01/2021 -
List item
News: EMA 2017 annual report published
Last updated: 02/05/2018 -
List item
Annual reports and work programmes
Last updated: 15/06/2020 -
List item
CHMP: meeting archive 2016-2018
Last updated: 26/02/2020 -
List item
News: Progress in science, medicine and health
Last updated: 17/05/2016 -
List item
CHMP: meeting archive 2013-2015
Last updated: 12/05/2016 -
List item
News: Progress on science, medicines and health
Last updated: 10/05/2017